Signs, Portents, and Immuno-Oncology Biomarkers

07:10 EDT 1 May 2019 | Genetic Engineering News

When translational researchers, drug developers, and clinical scientists seek immuno-oncology (IO) foresight, they often find it in biomarkers—or better still, the patterns formed by multiple biomarkers. Single biomarkers convey little of cancer’s complexity, leaving much unclear about the signaling pathways that sustain or suppress malignancies, the mechanisms that activate or deactivate specific immune defenses, or […]

The post Signs, Portents, and Immuno-Oncology Biomarkers appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: Signs, Portents, and Immuno-Oncology Biomarkers


More From BioPortfolio on "Signs, Portents, and Immuno-Oncology Biomarkers"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...